A new clinical trial sponsored by Cairo University is exploring an innovative approach to pain management during the insertion of the Copper T380A intrauterine device (IUD) for women who have previously undergone cesarean delivery. This trial compares a verbal analgesia technique to a standard neutral communication method during the procedure, aiming to optimize patient comfort.
What is the focus of this study?
This clinical trial focuses on comparing two distinct methods of communication during the insertion of the Copper T380A IUD in women with a prior cesarean delivery. The intervention highlights an innovative pain management technique called verbal analgesia, where clinicians use specific and reassuring language to potentially alleviate patient discomfort. For the control group, providers will follow a standardized neutral script and offer only procedural descriptions, such as “I am now placing the speculum.”
The study is currently in the recruiting phase, and further details, including updates about patient outcomes, will likely be shared in the future as data becomes available.
What is verbal analgesia?
Verbal analgesia involves using comforting, supportive, and therapeutic communication during medical procedures to manage pain and anxiety. The technique can include affirming statements, positive reinforcement, and clear explanations of each step to help patients feel at ease. While this approach does not replace pharmacological pain management, it is often employed as an adjunctive measure to improve patient experiences, particularly for procedures known to cause discomfort, such as IUD insertions.
Who is eligible for participation?
The trial is recruiting women who meet specific inclusion criteria. Eligible participants are individuals seeking contraceptive options and opting for the Copper T380A IUD, with a history of previous cesarean delivery. Additional inclusion or exclusion parameters may exist, and interested candidates are encouraged to review details on the ClinicalTrials.gov listing or to consult their healthcare provider directly for further eligibility clarification.
Why is this study important?
Pain management during IUD insertion is a significant concern for many patients, particularly those with medical histories, such as prior cesarean deliveries, which may increase procedural difficulty and sensitivity. Understanding the efficacy of verbal analgesia as a standalone or complementary technique could improve clinical practice guidelines, making IUD insertions less intimidating and more accessible for diverse patients.
The Copper T380A IUD is a widely used, hormone-free contraceptive method that requires precise insertion. Exploring patient-centric pain management strategies for this device reinforces broader efforts to prioritize women’s healthcare experiences and outcomes.
FAQs
- What is the Copper T380A IUD?
The Copper T380A is a hormone-free intrauterine contraceptive device designed for long-term use, typically up to 10 years. - Is verbal analgesia a replacement for pain medications?
No, verbal analgesia serves as an additional measure to enhance patient comfort but does not replace pharmacological pain control when required. - Where is this study being conducted?
The trial is sponsored by Cairo University, with specific site details available on the ClinicalTrials.gov webpage. - How can interested participants join?
Individuals can visit the ClinicalTrials.gov listing linked below or consult their healthcare provider for guidance on enrollment.
Key takeaways
This ongoing study by Cairo University seeks to advance pain management strategies for women undergoing Copper T380A IUD insertion. By comparing verbal analgesia with a standard neutral communication script, the trial hopes to enhance patient care, especially for women with prior cesarean deliveries.
Its findings could redirect clinical best practices by addressing an often-overlooked aspect of patient comfort during procedures.
Disclaimer
This post is intended for healthcare professionals and regulatory audiences. It does not provide medical or legal advice. Always refer to official clinical trial records for precise details.
Announcement details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07326007?term=medical+device